StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

TScan Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

TScan Therapeutics's price to sales ratio was 3.4× on Nov 11, 2026, against 16.8× a year earlier. Over the last 4 years it ranged from 2.0× to 83.5×, with a median of 15.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.4×−11.7
2025Dec 31, 202515.1×−19.1
2024Dec 31, 202434.3×+17.9
2023Dec 29, 202316.4×+12.9
2022Jan 31, 20223.5×+0.2
2021Dec 31, 20213.3×–

More TScan Therapeutics figures

See a number that looks wrong?